Founded earlier this year to develop other firms’ candidates to intercept or prevent immune-mediated diseases, Provention Bio Inc. added its first two clinical candidates – both targeted at inflammatory bowel disease – by licensing a pair of candidates Sept. 21 from Janssen Pharmaceutica NV.
Not coincidentally, Janssen parent Johnson & Johnson is focused on moving beyond traditional treatment of diseases, having launched a Disease Interception Accelerator in February 2015 to predict and preempt...
After New Jersey-based Provention made its debut in April with a $28.4m Series A financing – with participation from the Johnson & Johnson Innovation Fund – it landed its first...